Ibnsina PharmaCAI:ISPH +1.92%85 OCF Margin % is 2.33% as of Mar. 2026, which is 1564% above its 10-year median of 0.14. GuruFocus rates CAI:ISPH with a GF Score™ of 85/100 and a GF Value™ of E£10.46 (Modestly Overvalued). The stock has 7 warning signs investors should review. Among 116 Medical Distribution companies, Ibnsina Pharma ranks better than 51.72% on this metric.
The historical rank and industry rank for Ibnsina Pharma's OCF Margin % or its related term are showing as below:
CAI:ISPH'
s OCF Margin % Range Over the Past 10 Years
Min: -2.28 Med: 0.14 Max: 4.55
Current: 2.4
During the past 10 years, the highest OCF Margin % of Ibnsina Pharma was 4.55%. The lowest was -2.28%. And the median was 0.14%.
CAI:ISPH's OCF Margin % is ranked better than 51.72% of 116
companies
in the Medical Distribution industry
Industry Median: 2.165
vs CAI:ISPH: 2.40
Ibnsina Pharma OCF Margin % Related Terms
Ibnsina Pharma OCF Margin % Historical Data
* Premium members only.
The historical data trend for Ibnsina Pharma's OCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CAI:ISPH vs MCK, CAH, COR: OCF Margin % Comparison
For the Medical Distribution subindustry, Ibnsina Pharma's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ibnsina Pharma OCF Margin % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Ibnsina Pharma's OCF Margin % distribution charts can be found below:
* The bar in red indicates where Ibnsina Pharma's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ibnsina Pharma (CAI:ISPH) has a OCF Margin % of 2.33% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Ibnsina Pharma and its competitors. This is 1564% above median its historical median of 0.14. According to the industry distribution chart, Ibnsina Pharma ranks #56 out of 116 companies in the Medical Distribution industry, placing it in the top 48.3%.
Is Ibnsina Pharma's OCF Margin % too high?
Ibnsina Pharma's current OCF Margin % of 2.33% is 1564% above median its 10-year median of 0.14. The Medical Distribution industry median OCF Margin % is 2.17. Ibnsina Pharma's value of 2.33% is 7.6% above this industry median. Based on the distribution chart, Ibnsina Pharma ranks #56 out of 116 companies in the Medical Distribution industry, which is above the industry midpoint. Overall, Ibnsina Pharma has a GF Score™ of 85/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ibnsina Pharma's OCF Margin % compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Ibnsina Pharma ranks #56 out of 116 companies for OCF Margin %. This puts Ibnsina Pharma in the upper half of its industry. The industry median OCF Margin % is 2.17. Ibnsina Pharma's value of 2.33% is 7.6% above this benchmark. While the company's 10-year median is 0.14 vs. the industry median of 2.17, Ibnsina Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Medical Distribution company?
The median OCF Margin % among Medical Distribution companies is 2.17, based on 116 companies in the industry. Companies in the top quartile (top 25%) have a OCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ibnsina Pharma's current OCF Margin % of 2.33% is 7.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Ibnsina Pharma and its competitors. For the Medical Distribution industry, the median OCF Margin % is 2.17 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ibnsina Pharma's current OCF Margin % is 2.33%, which is 1564% above median its own 10-year median of 0.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ibnsina Pharma stock overvalued right now?
Based on GuruFocus' analysis, Ibnsina Pharma (CAI:ISPH) is currently considered Modestly Overvalued. The stock's GF Value™ is E£10.46, compared to a current price of E£11.67 — trading 11.6% above its estimated fair value. The current OCF Margin % is 2.33%, which is 1564% above median its 10-year median of 0.14 and 7.6% above the Medical Distribution industry median of 2.17. Ibnsina Pharma's overall GF Score™ is 85/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Ibnsina Pharma (CAI:ISPH), the current OCF Margin % is 2.33% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ibnsina Pharma (CAI:ISPH) Overvalued in 2026?
Based on GuruFocus' analysis, Ibnsina Pharma stock appears to be overvalued.
The current stock price of E£11.67 is trading 11.6% above its estimated GF Value™ of E£10.46.
GuruFocus considers Ibnsina Pharma to be Modestly Overvalued.
Key valuation signals for CAI:ISPH:
OCF Margin %: 2.33% (1564% above median its 10-year median of 0.14)
GF Value™: E£10.46 vs. price of E£11.67 (11.6% above fair value)
Industry Position: 7.6% above the Medical Distribution median (#56 of 116)
No single metric tells the full story. See the CAI:ISPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ibnsina Pharma is an Egypt-based pharmaceutical distribution company. It is engaged in purchasing and selling in wholesale and distribution of pharmaceutical, semi- pharmaceutical, and cosmetic products. It distributes a portfolio of pharmaceutical products from local and multinational pharmaceutical companies to retail pharmacies, wholesalers, hospitals, and public health institutions. In addition, the company also offers services including warehousing and logistics, marketing solutions, importation, packaging, market research, and analysis.
85GF Score
Get the complete analysis for CAI:ISPH
OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CAI:ISPH has been successfully added to your 
